Argent Biopharma Ltd (AU:RGT) — Market Cap & Net Worth
Market Cap & Net Worth: Argent Biopharma Ltd (RGT)
Argent Biopharma Ltd (AU:RGT) has a market capitalization of $2.34 Million (AU$3.30 Million) as of May 3, 2026. Listed on the AU stock exchange, this Australia-based company holds position #29514 globally and #1742 in its home market, demonstrating a -13.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Argent Biopharma Ltd's stock price AU$0.04 by its total outstanding shares 86942317 (86.94 Million). Analyse Argent Biopharma Ltd (RGT) cash conversion ratio to see how efficiently the company converts income to cash.
Argent Biopharma Ltd Market Cap History: 2015 to 2026
Argent Biopharma Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.60 Billion to $2.34 Million (-44.57% CAGR).
Argent Biopharma Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Argent Biopharma Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.38x
Argent Biopharma Ltd's market cap is 7.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.65 Billion | $2.20K | -$6.16 Million | 1204024.04x | N/A |
| 2017 | $5.48 Billion | $120.24K | -$8.14 Million | 45533.45x | N/A |
| 2018 | $2.46 Billion | $296.81K | -$8.25 Million | 8290.42x | N/A |
| 2019 | $1.97 Billion | $656.24K | -$11.01 Million | 2999.76x | N/A |
| 2020 | $1.54 Billion | $2.08 Million | -$19.36 Million | 739.69x | N/A |
| 2021 | $2.28 Billion | $3.00 Million | -$15.87 Million | 759.71x | N/A |
| 2022 | $676.69 Million | $4.73 Million | -$16.77 Million | 143.00x | N/A |
| 2023 | $29.22 Million | $3.39 Million | -$20.82 Million | 8.63x | N/A |
| 2024 | $10.46 Million | $891.08K | -$17.53 Million | 11.74x | N/A |
| 2025 | $4.31 Million | $583.45K | -$17.84 Million | 7.38x | N/A |
Competitor Companies of RGT by Market Capitalization
Companies near Argent Biopharma Ltd in the global market cap rankings as of May 3, 2026.
Key companies related to Argent Biopharma Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Argent Biopharma Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Argent Biopharma Ltd's market cap moved from $1.60 Billion to $ 2.34 Million, with a yearly change of -44.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$2.34 Million | -45.71% |
| 2025 | AU$4.31 Million | -58.82% |
| 2024 | AU$10.46 Million | -64.21% |
| 2023 | AU$29.22 Million | -95.68% |
| 2022 | AU$676.69 Million | -70.27% |
| 2021 | AU$2.28 Billion | +48.00% |
| 2020 | AU$1.54 Billion | -21.88% |
| 2019 | AU$1.97 Billion | -20.00% |
| 2018 | AU$2.46 Billion | -55.06% |
| 2017 | AU$5.48 Billion | +106.98% |
| 2016 | AU$2.65 Billion | +65.38% |
| 2015 | AU$1.60 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Argent Biopharma Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.34 Million USD |
| MoneyControl | $2.34 Million USD |
| MarketWatch | $2.34 Million USD |
| marketcap.company | $2.34 Million USD |
| Reuters | $2.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Argent Biopharma Ltd
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I c… Read more